Literature DB >> 25160627

A fusion intermediate gp41 immunogen elicits neutralizing antibodies to HIV-1.

Rachel P J Lai1, Miriam Hock2, Jens Radzimanowski2, Paul Tonks1, David Lutje Hulsik2, Gregory Effantin2, David J Seilly1, Hanna Dreja1, Alexander Kliche3, Ralf Wagner3, Susan W Barnett4, Nancy Tumba5, Lynn Morris5, Celia C LaBranche6, David C Montefiori6, Michael S Seaman7, Jonathan L Heeney8, Winfried Weissenhorn9.   

Abstract

The membrane-proximal external region (MPER) of the human immunodeficiency virus, type 1 (HIV-1) envelope glycoprotein subunit gp41 is targeted by potent broadly neutralizing antibodies 2F5, 4E10, and 10E8. These antibodies recognize linear epitopes and have been suggested to target the fusion intermediate conformation of gp41 that bridges viral and cellular membranes. Anti-MPER antibodies exert different degrees of membrane interaction, which is considered to be the limiting factor for the generation of such antibodies by immunization. Here we characterize a fusion intermediate conformation of gp41 (gp41(int)-Cys) and show that it folds into an elongated ∼ 12-nm-long extended structure based on small angle x-ray scattering data. Gp41(int)-Cys was covalently linked to liposomes via its C-terminal cysteine and used as immunogen. The gp41(int)-Cys proteoliposomes were administered alone or in prime-boost regimen with trimeric envelope gp140(CA018) in guinea pigs and elicited high anti-gp41 IgG titers. The sera interacted with a peptide spanning the MPER region, demonstrated competition with broadly neutralizing antibodies 2F5 and 4E10, and exerted modest lipid binding, indicating the presence of MPER-specific antibodies. Although the neutralization potency generated solely by gp140(CA018) was higher than that induced by gp41(int)-Cys, the majority of animals immunized with gp41(int)-Cys proteoliposomes induced modest breadth and potency in neutralizing tier 1 pseudoviruses and replication-competent simian/human immunodeficiency viruses in the TZM-bl assay as well as responses against tier 2 HIV-1 in the A3R5 neutralization assay. Our data thus demonstrate that liposomal gp41 MPER formulation can induce neutralization activity, and the strategy serves to improve breadth and potency of such antibodies by improved vaccination protocols.
© 2014 by The American Society for Biochemistry and Molecular Biology, Inc.

Entities:  

Keywords:  AIDS; HIV-1; HIV-1 gp41; Membrane Fusion; Protein Conformation; Vaccine Development; X-ray Scattering

Mesh:

Substances:

Year:  2014        PMID: 25160627      PMCID: PMC4208001          DOI: 10.1074/jbc.M114.569566

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  114 in total

1.  HIV-1 vaccine development: constrained peptide immunogens show improved binding to the anti-HIV-1 gp41 MAb.

Authors:  G B McGaughey; M Citron; R C Danzeisen; R M Freidinger; V M Garsky; W M Hurni; J G Joyce; X Liang; M Miller; J Shiver; M J Bogusky
Journal:  Biochemistry       Date:  2003-03-25       Impact factor: 3.162

2.  Synthesis, conformation, and immunogenicity of monosaccharide-centered multivalent HIV-1 gp41 peptides containing the sequence of DP178.

Authors:  Jiahong Ni; Robert Powell; Ilia V Baskakov; Anthony DeVico; George K Lewis; Lai-Xi Wang
Journal:  Bioorg Med Chem       Date:  2004-06-15       Impact factor: 3.641

3.  ELISA for antibodies to lipid A, lipopolysaccharides and other hydrophobic antigens.

Authors:  M A Freudenberg; A Fomsgaard; I Mitov; C Galanos
Journal:  Infection       Date:  1989 Sep-Oct       Impact factor: 3.553

4.  A potent cross-clade neutralizing human monoclonal antibody against a novel epitope on gp41 of human immunodeficiency virus type 1.

Authors:  G Stiegler; R Kunert; M Purtscher; S Wolbank; R Voglauer; F Steindl; H Katinger
Journal:  AIDS Res Hum Retroviruses       Date:  2001-12-10       Impact factor: 2.205

5.  Chimeric plant virus particles as immunogens for inducing murine and human immune responses against human immunodeficiency virus type 1.

Authors:  C Marusic; P Rizza; L Lattanzi; C Mancini; M Spada; F Belardelli; E Benvenuto; I Capone
Journal:  J Virol       Date:  2001-09       Impact factor: 5.103

6.  Purification and characterization of oligomeric envelope glycoprotein from a primary R5 subtype B human immunodeficiency virus.

Authors:  Indresh K Srivastava; Leonidas Stamatatos; Harold Legg; Elaine Kan; Anne Fong; Stephen R Coates; Louisa Leung; Mark Wininger; John J Donnelly; Jeffrey B Ulmer; Susan W Barnett
Journal:  J Virol       Date:  2002-03       Impact factor: 5.103

7.  Enhancement of alpha -helicity in the HIV-1 inhibitory peptide DP178 leads to an increased affinity for human monoclonal antibody 2F5 but does not elicit neutralizing responses in vitro. Implications for vaccine design.

Authors:  Joseph G Joyce; William M Hurni; Michael J Bogusky; Victor M Garsky; Xiaoping Liang; Michael P Citron; Renee C Danzeisen; Michael D Miller; John W Shiver; Paul M Keller
Journal:  J Biol Chem       Date:  2002-09-16       Impact factor: 5.157

8.  Broadly neutralizing antibodies targeted to the membrane-proximal external region of human immunodeficiency virus type 1 glycoprotein gp41.

Authors:  M B Zwick; A F Labrijn; M Wang; C Spenlehauer; E O Saphire; J M Binley; J P Moore; G Stiegler; H Katinger; D R Burton; P W Parren
Journal:  J Virol       Date:  2001-11       Impact factor: 5.103

9.  Induction of mucosal and systemic neutralizing antibodies against human immunodeficiency virus type 1 (HIV-1) by oral immunization with bovine Papillomavirus-HIV-1 gp41 chimeric virus-like particles.

Authors:  Hongtao Zhang; Yujun Huang; Raja Fayad; Gregory T Spear; Liang Qiao
Journal:  J Virol       Date:  2004-08       Impact factor: 5.103

10.  Structure and mechanistic analysis of the anti-human immunodeficiency virus type 1 antibody 2F5 in complex with its gp41 epitope.

Authors:  Gilad Ofek; Min Tang; Anna Sambor; Hermann Katinger; John R Mascola; Richard Wyatt; Peter D Kwong
Journal:  J Virol       Date:  2004-10       Impact factor: 5.103

View more
  14 in total

Review 1.  Evolution of B cell analysis and Env trimer redesign.

Authors:  Gunilla B Karlsson Hedestam; Javier Guenaga; Martin Corcoran; Richard T Wyatt
Journal:  Immunol Rev       Date:  2017-01       Impact factor: 12.988

2.  Modulating immunogenic properties of HIV-1 gp41 membrane-proximal external region by destabilizing six-helix bundle structure.

Authors:  Saikat Banerjee; Heliang Shi; Habtom H Habte; Yali Qin; Michael W Cho
Journal:  Virology       Date:  2016-01-21       Impact factor: 3.616

3.  Immunogenic properties of a trimeric gp41-based immunogen containing an exposed membrane-proximal external region.

Authors:  Habtom H Habte; Saikat Banerjee; Heliang Shi; Yali Qin; Michael W Cho
Journal:  Virology       Date:  2015-10-09       Impact factor: 3.616

4.  The C34 Peptide Fusion Inhibitor Binds to the Six-Helix Bundle Core Domain of HIV-1 gp41 by Displacement of the C-Terminal Helical Repeat Region.

Authors:  John M Louis; James L Baber; G Marius Clore
Journal:  Biochemistry       Date:  2015-11-09       Impact factor: 3.162

5.  Proteoliposomal formulations of an HIV-1 gp41-based miniprotein elicit a lipid-dependent immunodominant response overlapping the 2F5 binding motif.

Authors:  Luis M Molinos-Albert; Eneritz Bilbao; Luis Agulló; Silvia Marfil; Elisabet García; Maria Luisa Rodríguez de la Concepción; Nuria Izquierdo-Useros; Cristina Vilaplana; Jon A Nieto-Garai; F-Xabier Contreras; Martin Floor; Pere J Cardona; Javier Martinez-Picado; Bonaventura Clotet; Jordi Villà-Freixa; Maier Lorizate; Jorge Carrillo; Julià Blanco
Journal:  Sci Rep       Date:  2017-01-13       Impact factor: 4.379

6.  Immunization with HIV-1 envelope T20-encoding DNA vaccines elicits cross-clade neutralizing antibody responses.

Authors:  S Stenler; K E Lundin; L Hansen; S Petkov; N Mozafari; M Isaguliants; P Blomberg; C I E Smith; D M Goldenberg; C-H Chang; K Ljungberg; J Hinkula; B Wahren
Journal:  Hum Vaccin Immunother       Date:  2017-07-11       Impact factor: 3.452

Review 7.  Resources to Discover and Use Short Linear Motifs in Viral Proteins.

Authors:  Peter Hraber; Paul E O'Maille; Andrew Silberfarb; Katie Davis-Anderson; Nicholas Generous; Benjamin H McMahon; Jeanne M Fair
Journal:  Trends Biotechnol       Date:  2019-08-16       Impact factor: 19.536

Review 8.  Immunologic Insights on the Membrane Proximal External Region: A Major Human Immunodeficiency Virus Type-1 Vaccine Target.

Authors:  Luis M Molinos-Albert; Bonaventura Clotet; Julià Blanco; Jorge Carrillo
Journal:  Front Immunol       Date:  2017-09-19       Impact factor: 7.561

9.  Structural Basis for Broad HIV-1 Neutralization by the MPER-Specific Human Broadly Neutralizing Antibody LN01.

Authors:  Dora Pinto; Craig Fenwick; Christophe Caillat; Chiara Silacci; Serafima Guseva; François Dehez; Christophe Chipot; Sonia Barbieri; Andrea Minola; David Jarrossay; Georgia D Tomaras; Xiaoying Shen; Agostino Riva; Maciej Tarkowski; Olivier Schwartz; Timothée Bruel; Jérémy Dufloo; Michael S Seaman; David C Montefiori; Antonio Lanzavecchia; Davide Corti; Giuseppe Pantaleo; Winfried Weissenhorn
Journal:  Cell Host Microbe       Date:  2019-10-22       Impact factor: 21.023

Review 10.  Neutralizing Antibodies Targeting HIV-1 gp41.

Authors:  Christophe Caillat; Delphine Guilligay; Guidenn Sulbaran; Winfried Weissenhorn
Journal:  Viruses       Date:  2020-10-23       Impact factor: 5.048

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.